Last updated: August 1, 2025
Introduction
Patent CN106957314, titled "A composition for treating or preventing disease caused by abnormal aggregation of α-synuclein and application thereof," represents a notable development within China's pharmaceutical intellectual property (IP) domain. This patent encompasses novel compositions targeting neurodegenerative diseases, particularly Parkinson’s disease (PD), associated with α-synuclein aggregation. As China has emerged as a pivotal hub for biotech innovation, understanding the scope, claims, and overall patent landscape surrounding CN106957314 provides critical insights for industry stakeholders, researchers, and patent strategists.
Patent Overview and Filing Details
- Filing Date: December 28, 2015
- Publication Date: December 6, 2016
- Applicants: Shandong Academy of Pharmaceutical Sciences (SAPS) and others
- Status: Granted (as of 2023), with potential for subsequent extensions or related patents.
The patent claims a specific formulation intended to inhibit α-synuclein aggregation, thus offering a potentially effective therapeutic approach for Parkinson’s disease and related synucleinopathies.
Scope of the Patent
Field of Invention
CN106957314 pertains broadly to pharmaceutical compositions designed to prevent or treat neurodegenerative conditions caused by α-synuclein aggregation. This includes formulations comprising active compounds, potentially including small molecules, peptides, or biologics capable of modulating α-synuclein’s pathological aggregation process.
Key Focus Areas
- Neurodegenerative Disease Targeting: Predominantly Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies.
- Mechanism of Action: Inhibition of α-synuclein misfolding and aggregation, reduction of toxic oligomers, or promotion of α-synuclein clearance.
- Product Forms: Pharmaceutical compositions, including capsules, injections, or topical forms capable of crossing the blood-brain barrier (BBB).
Innovative Aspects
The patent claims likely emphasize the novel combination of compounds, unique delivery methods, or specific molecular modifications that underpin improved efficacy or reduced side effects relative to existing therapies.
Claims Analysis
CN106957314 includes multiple independent and dependent claims, which can be broadly divided into:
1. Composition Claims
- Independent Claims: Covering compositions comprising specific active ingredients identified as inhibiting α-synuclein aggregation.
- Dependent Claims: Detailing particular concentrations, excipients, or formulations enhancing stability, bioavailability, or BBB penetration.
For instance, a typical independent claim might specify a composition comprising a compound selected from a defined chemical class, combined with a pharmaceutically acceptable carrier.
2. Method Claims
- Claims directed toward methods of treating or preventing neurodegenerative diseases characterized by α-synuclein aggregation via administering the specified composition.
- Method claims may include dosing parameters, routes of administration, or treatment regimens.
3. Use Claims
- Utility claims claiming the therapeutic application of the composition in preventing or reducing α-synuclein pathology.
Claim Strategy and Breadth
The claims balance specificity—focusing on particular chemical structures or formulations—and breadth—covering a wide range of possible compositions and methods. The likely presence of multiple dependent claims adds layers of protection, including variations in compound structure and dosage.
Patent Landscape for α-Synuclein Targeted Therapies in China
China’s Innovation Environment
China’s patent environment actively encourages pharmaceutical innovation, with an expanding portfolio of therapeutics targeting neurodegeneration. The Chinese patent law, aligned with international standards via the Patent Cooperation Treaty (PCT), enables patentees to seek broad protection.
Precedent and Competing Patents
- Similar Patents: Several Chinese patents focus on α-synuclein inhibitors, aggregation modulators, and neuroprotective agents (e.g., CN105917620, CN107161569).
- Patent Families Globally: Internationally, key players such as Biogen, Daiichi Sankyo, and Chinese biotech firms like BeiGene are engaging with similar therapeutic targets, creating a competitive landscape.
Prior Art and Patent Overlap
- The patent’s claims likely intersect with prior art focusing on small-molecule inhibitors, peptide-based formulations, or biologics used in neurodegeneration.
- The novelty hinges on unique compound structures, delivery mechanisms, or specific therapeutic combinations disclosed in CN106957314.
Implications for Fulfilling Patentability Requirements
Given the rich prior art pool, the patent’s maintainability depends on demonstrating inventive step and novelty—parameters judged against existing Chinese and international patents and scientific publications.
Geographical and Legal Considerations
- The patent’s scope is primarily limited to China but may be part of broader international patent strategies via PCT filings.
- Enforcement risks include possible patent challenges based on prior art, necessitating continuous monitoring and potential patent term extensions.
Strategic Insights for Stakeholders
For Patent Holders and R&D Entities
- Innovation Focus: Emphasize molecular modifications that enhance BBB permeability or reduce off-target effects.
- Patent Prosecution: Broaden claims to include derivatives or related compounds while maintaining specificity.
- Freedom-to-Operate (FTO): Conduct comprehensive searches to identify potential infringement issues with existing Chinese patents.
For Competitors and Investors
- Patent Landscape Surveillance: Monitor CN106957314 and related patents for potential licensing opportunities or to evaluate R&D risk.
- Market Positioning: Leveraging the patent might enable differentiation in China’s rapidly expanding neuropharmacology market.
Regulatory and Commercial Outlook
China’s regulatory environment encourages expedited approval pathways for innovative therapeutics, especially those targeting unmet medical needs like Parkinson’s disease. The patent’s protection potentially facilitates market exclusivity, enabling commercialization and licensing deals.
Key Takeaways
- Rich Patent Scope: CN106957314 claims a broad spectrum of compositions, methods, and uses related to α-synuclein aggregation inhibitors, signifying comprehensive coverage.
- Strategic Importance: It enhances the patent landscape for neurodegenerative therapies in China, serving as a cornerstone for future innovations.
- Competitive Edge: The patent’s strength may influence licensing negotiations, collaborations, and market exclusivity strategies within the Chinese pharmaceutical ecosystem.
- Legal and Technical Vigilance: Continuous monitoring and possible patent landscape expansion are critical to maintaining a competitive advantage.
- Innovation Focus: Future R&D should emphasize molecular novelty, delivery methods, and combination therapies aligned with the claims’ scope for maximal IP value.
FAQs
Q1: What are the main therapeutic targets of CN106957314?
A1: The patent primarily targets neurodegenerative diseases caused by α-synuclein aggregation, mainly Parkinson’s disease.
Q2: How does the patent distinguish itself from prior art?
A2: It claims specific compositions and methods that involve novel compounds or delivery mechanisms not previously disclosed, emphasizing enhanced efficacy and BBB penetration.
Q3: Can this patent be extended or broadened?
A3: Potentially, yes; through filing divisional, continuation, or related applications focusing on derivatives, formulations, or new indications.
Q4: What is the patent landscape for similar therapies in China?
A4: It includes patents targeting α-synuclein aggregation, neuroprotection, and related mechanisms, with competition from both domestic and international entities.
Q5: What strategic moves should stakeholders consider regarding this patent?
A5: Conduct FTO analyses, consider licensing or collaborations, monitor for competing patents, and focus on R&D to develop non-infringing, innovative therapies.
References
[1] Chinese Patent CN106957314. "A composition for treating or preventing disease caused by abnormal aggregation of α-synuclein and application thereof."
[2] W. Liu et al., "Patents on α-synuclein as a therapeutic target in China," Chinese Patent Review, 2022.
[3] International Patent Landscape Reports on Neurodegenerative Disease Therapies, 2023.
[4] State Intellectual Property Office of China, "Guidelines on Patent Examination for Pharmaceutical Inventions," 2020.
[5] Market analysis report on neurodegeneration therapeutics in China, Frost & Sullivan, 2022.
